Volitionrx Limited · AMEX:VNRX
Volitionrx — Technical Presentation (February 2024)
5 slides from Volitionrx's technical presentation, February 2024
Slide 1: NucleoCapture: Therapeutic Removal of NETs from Blood in a Pig Model of Sepsis
NucleoCapture Therapeutic Removal of Neutrophil Extracellular Traps from Blood in a Pig Model of Sepsis Dr Andrew Aswani Guy’s and St Thomas’ Hospitals, London Santersus AG [email protected]
Slide 2: Overlooked Danger of Neutrophil Extracellular Traps
Overlooked Danger of Neutrophil Extracellular Traps NucleoCapture has the potential to transform the treatment paradigm of unmet medical diseases Neutrophils make up the largest fraction of blood cells produced by the bone marrow with a 100 billion cells produced daily. This amount might triple in c
Slide 3: NucleoCapture: Novel first-in-class NET depletion
NucleoCapture: Novel first-in-class NET depletion Utilising Linker Histone H1.3 binding • In contrast to any potential NET-focused pharmacological interventions NucleoCapture allows the safe removal of excess NETs from blood without compromising the defensive functions of neutrophils • NucleoCapture
Slide 4: Shock Resolution With NucleoCapture
Shock Resolution With NucleoCapture Vasopressor Use 100-fold lower Lactate 50% lower 15000 Norepinephrine (mg) 10 10000 SHAM NUCLEOCAPTURE 5000 0 Lactate (mmol/L) re tu am ap Sh oC le uc 5 N Urine Output 2-fold higher 1000 Urine Output (ml) 800 600 0 400 0 1 2 3 4 5 6 7 Time (h) E. coli 200 0 Plasma
Slide 5: Marked NET Clearance with NucleoCapture: Up to 99% removed from Plasma
Marked NET Clearance with NucleoCapture: Up to 99% removed from Plasma Systemic Pre-Column Post-Column 400 Sham Control 350 H3.1-nucleosomes (ng/ml) NucleoCapture 300 250 200 150 100 50 0 0 1 2 3 4 5 6 7 3 4 5 6 7 3 4 5 6 7 Time (h) E.coli Control pig Treated pig Plasmapheresis Immunoassay of cell f